Federal Agency Advises Against Using Federal Funds for Fentanyl Test Strips

Overview

The Substance Abuse and Mental Health Services Administration (SAMHSA) issued guidance advising against the use of federal funds to purchase fentanyl testing strips and other harm reduction supplies. The agency also emphasized that opioid addiction medications should be used alongside support services rather than as standalone treatments.

Background

Harm reduction strategies, including the distribution of fentanyl test strips and sterile injection supplies, have been widely promoted to reduce overdose deaths and infectious disease transmission among people who use illicit drugs. Medications such as methadone and buprenorphine are proven to reduce opioid overdose mortality and are standard treatments for opioid use disorder. The Trump administration's SAMHSA has shifted policy away from harm reduction approaches, favoring abstinence-first interventions and emphasizing law enforcement. This marks a reversal from prior federal support for test strip distribution and harm reduction services.

Data Highlights

SAMHSA cancelled approximately $1.7 billion in block grant funding and cut another $350 million in addiction and overdose prevention funding. The agency's workforce decreased from roughly 900 to less than half under the Trump administration.

Key Findings

• SAMHSA warned grantees against using federal funds to purchase fentanyl, xylazine, and medetomidine test strips for public distribution.
• Federal funds may still be used for test strips in professional settings such as by law enforcement and medical workers.
• Funding for sterile syringes, pipes, overdose hotlines, and other paraphernalia perceived to facilitate drug use is discouraged.
• Medications for opioid use disorder like methadone and buprenorphine should be used as part of a pathway to recovery, not as indefinite treatments without support services.
• The agency encourages annual discussions between clinicians and patients about continuing medication treatment.
• These policies contrast with prior federal support under the Biden administration and current addiction medicine guidelines advocating medication access even without psychosocial treatment.

Clinical Implications

Clinicians should be aware of the federal restrictions on funding for harm reduction supplies and the emphasis on combining medication with psychosocial support. Despite policy shifts, evidence-based practice supports continued access to opioid use disorder medications regardless of patient participation in counseling. Providers may need to advocate for patient-centered care that balances medication access with supportive services.

Conclusion

SAMHSA's recent guidance represents a significant policy shift away from harm reduction and standalone medication treatments for opioid use disorder, potentially impacting funding and clinical practices. Ongoing dialogue between addiction medicine professionals and federal agencies is essential to align policies with evidence-based care.

References

1. STAT News/2024 -- Federal Agency Advises Against Allocating Federal Funds for Fentanyl Testing Strips